6667 — Mega Genomics Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapHigh Flyer

Annual income statement for Mega Genomics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	124	203	237	146	151
Cost of Revenue
Gross Profit	78.5	146	167	81.7	88.3
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	65.8	91.8	134	166	114
Operating Profit	57.9	111	103	-20.7	37.3
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	38.3	94.9	95.9	-21.4	36.2
Provision for Income Taxes
Net Income After Taxes	29.7	79.1	79	-17.6	30
Net Income Before Extraordinary Items
Net Income	29.7	79.1	79	-17.6	30
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	29.7	79.1	79	-17.6	30
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.124	0.331	0.398	-0.037	0.142